{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:37:12Z","timestamp":1795081032339,"version":"4.10.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clgc.2021.12.014","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T11:40:20Z","timestamp":1640346020000},"page":"176-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-5913","authenticated-orcid":false,"given":"Mehrad","family":"Adibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrett","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minas P.","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Petros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.12.014_bib0001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2004.04.011","article-title":"EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma","volume":"46","author":"Oosterlinck","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0002","first-page":"43","article-title":"Cancer statistics","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2021.12.014_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.1991.tb15064.x","article-title":"Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences","volume":"67","author":"Krogh","year":"1991","journal-title":"Br J Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0004","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euf.2014.12.006","article-title":"Smoking status is not sufficient to accurately target patients who would benefit from screening for bladder and kidney cancer","volume":"1","author":"Roupret","year":"2015","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2021.12.014_bib0006","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.12.014_bib0007","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/ncpuro0875","article-title":"Management of patients with upper urinary tract transitional cell carcinoma","volume":"4","author":"Raman","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0008","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma","volume":"71","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0009","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","article-title":"Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma","volume":"35","author":"Seisen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1464-410X.2012.11413.x","article-title":"Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) - opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial","volume":"110","author":"Birtle","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2021.12.014_bib0011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/end.2016.0525","article-title":"Comparative analysis of renal functional outcomes and overall survival of elderly vs nonelderly patients undergoing radical nephrectomy","volume":"31","author":"Peyton","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ucl.2017.12.002","article-title":"Optimal timing of chemotherapy and surgery in patients with muscle-invasive bladder cancer and upper urinary tract urothelial carcinoma","volume":"45","author":"Tabayoyong","year":"2018","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2021.12.014_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0015","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Matin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.12.014_bib0016","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.12.014_bib0017","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","author":"Margulis","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0018","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Eurol"},{"issue":"4","key":"10.1016\/j.clgc.2021.12.014_bib0019","first-page":"e999","article-title":"Multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma","volume":"201","author":"Coleman","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0020","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.1464-410X.2011.10075.x","article-title":"Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration","volume":"108","author":"Youssef","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2021.12.014_bib0021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2019.01.058","article-title":"High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma","volume":"129","author":"Meng","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2021.12.014_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2015.12.007","article-title":"Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study","volume":"89","author":"Siefker-Radtke","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2021.12.014_bib0023","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1002\/cncr.26172","article-title":"Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study","volume":"117","author":"Vassilakopoulou","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2021.12.014_bib0024","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2021.39.6_suppl.455","article-title":"Updated outcomes of POUT: a phase III randomized trial of peri-operative chemotherapy vs. surveillance in upper tract urothelial cancer","volume":"39","author":"Birtle","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncr.27751","article-title":"A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results","volume":"119","author":"Siefker-Radtke","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.12.014_bib0026","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.urolonc.2019.06.009","article-title":"Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma","volume":"37","author":"Freifeld","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2021.12.014_bib0027","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.urolonc.2018.12.002","article-title":"Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma","volume":"37","author":"Petros","year":"2019","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321002445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321002445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:16Z","timestamp":1761564916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321002445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1558767321002445"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.12.014","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}